Cost-effective treatment of atracurium resistance in critically ill patients.
S J
SJ
Tschida
L L
LL
Hoey
K
K
Vance-Bryan
D001279:Atracurium / Q000494:pharmacology*; D003362:Cost-Benefit Analysis; D016638:Critical Illness; D006801:Humans; D007546:Isoquinolines / Q000191:economics / Q000627:therapeutic use; D003473:Neuromuscular Nondepolarizing Agents / Q000191:economics* / Q000627:therapeutic use*; D010197:Pancuronium / Q000191:economics / Q000627:therapeutic use; D013618:Tachyphylaxis
D007546:Isoquinolines; D003473:Neuromuscular Nondepolarizing Agents; D001279:Atracurium; D010197:Pancuronium; C049429:doxacurium